aducanumab 14
It is the name of an experimental drug that is being developed to eliminate the harmful protein plaques amyloid-beta that is deposited in the brain in mild and initial phases of disease of Alzheimer.Esta being developed by the Biogen laboratories in Zurich, Switzerland.